Elder Pharma launches anti-fungal drug in India

Launched Zalain to treat fungal skin infections, plans to launch upto five nutraceutical products in India through partnerships with intt firms in 6 months

Elder Pharmaceuticals today said it has launched 'Zalain', a medicine used to treat fungal skin infections, in India in association with Spain-based drug firm Ferrer.

"Zalain has been introduced in India as part of company's strategy to strengthen its anti-infectives division which stood at about Rs 113.61 crore in FY 2012 and contributed 10% to the total revenue," Elder Pharmaceuticals Ltd Joint Managing Director Alok Saxena said in a statement.

The company is also planning to launch up to five in India through partnerships with international firms in next six months as it looks to strengthen position in the segment in the domestic market.

The Mumbai-based drug firm at present markets various in the country, including calcium supplement 'Shelcal'. Its product portfolio consists licensed as well as own brands.

Elder Pharma's revenues for the financial year ended March 2012 stood at Rs 981.89 crore.

Shares of today closed at Rs 302.15 on the BSE, up 2.25% from its previous close.

image
Business Standard
177 22
Business Standard

Elder Pharma launches anti-fungal drug in India

Launched Zalain to treat fungal skin infections, plans to launch upto five nutraceutical products in India through partnerships with intt firms in 6 months

Press Trust of India  |  New Delhi 

Elder Pharmaceuticals today said it has launched 'Zalain', a medicine used to treat fungal skin infections, in India in association with Spain-based drug firm Ferrer.

"Zalain has been introduced in India as part of company's strategy to strengthen its anti-infectives division which stood at about Rs 113.61 crore in FY 2012 and contributed 10% to the total revenue," Elder Pharmaceuticals Ltd Joint Managing Director Alok Saxena said in a statement.

The company is also planning to launch up to five in India through partnerships with international firms in next six months as it looks to strengthen position in the segment in the domestic market.

The Mumbai-based drug firm at present markets various in the country, including calcium supplement 'Shelcal'. Its product portfolio consists licensed as well as own brands.



Elder Pharma's revenues for the financial year ended March 2012 stood at Rs 981.89 crore.

Shares of today closed at Rs 302.15 on the BSE, up 2.25% from its previous close.

RECOMMENDED FOR YOU

Elder Pharma launches anti-fungal drug in India

Launched Zalain to treat fungal skin infections, plans to launch upto five nutraceutical products in India through partnerships with intt firms in 6 months

Elder Pharmaceuticals today said it has launched 'Zalain', a medicine used to treat fungal skin infections, in India in association with Spain-based drug firm Ferrer.

Elder Pharmaceuticals today said it has launched 'Zalain', a medicine used to treat fungal skin infections, in India in association with Spain-based drug firm Ferrer.

"Zalain has been introduced in India as part of company's strategy to strengthen its anti-infectives division which stood at about Rs 113.61 crore in FY 2012 and contributed 10% to the total revenue," Elder Pharmaceuticals Ltd Joint Managing Director Alok Saxena said in a statement.

The company is also planning to launch up to five in India through partnerships with international firms in next six months as it looks to strengthen position in the segment in the domestic market.

The Mumbai-based drug firm at present markets various in the country, including calcium supplement 'Shelcal'. Its product portfolio consists licensed as well as own brands.

Elder Pharma's revenues for the financial year ended March 2012 stood at Rs 981.89 crore.

Shares of today closed at Rs 302.15 on the BSE, up 2.25% from its previous close.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard